Contura
United Kingdom
UK-headquartered pan-European niche medical device and pharmaceutical company, with a focus on urology products
See website 
Corporate Overview
Read more
Products
Read more
Our team
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.
Read moreProducts
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.
Read moreBusiness Development
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.
Read moreJuno is led by a team of highly skilled experts, with decades of collective industry experience to drawn on, they offer a breadth of pharmaceutical knowledge. This knowledge paired with a genuine passion for innovation and to drive value consistently delivers superior outcomes for suppliers, customers and shareholders alike.
Standard Generics
Small molecule generics delivered in standard presentations.
Value Added Generics
Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Value Added Generics
Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Value Added Generics
Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Value Added Generics
Research-focused approach to deliver improved formulation, new presentations & improved user experience.
Ian has over 43 years of pharmaceutical industry experience. Prior to founding Juno/Cpoint in 2010, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010. He was instrumental in the development of Arrow’s international business units in South Africa and Brasil. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual Canadian sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Teva) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was Executive Vice President and General Manager of Genpharm, Canada. He was a Senior Executive in the international generics business of Amerpharm/Merck KGaA (now Mylan/Viatris) and served in the office of the President of Par Pharmaceuticals (US) for Merck Generics.
Read more
Ian has over 43 years of pharmaceutical industry experience. Prior to founding Juno/Cpoint in 2010, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010. He was instrumental in the development of Arrow’s international business units in South Africa and Brasil. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual Canadian sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Teva) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was Executive Vice President and General Manager of Genpharm, Canada. He was a Senior Executive in the international generics business of Amerpharm/Merck KGaA (now Mylan/Viatris) and served in the office of the President of Par Pharmaceuticals (US) for Merck Generics.
Read more
Ian has over 43 years of pharmaceutical industry experience. Prior to founding Juno/Cpoint in 2010, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010. He was instrumental in the development of Arrow’s international business units in South Africa and Brasil. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual Canadian sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Teva) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was Executive Vice President and General Manager of Genpharm, Canada. He was a Senior Executive in the international generics business of Amerpharm/Merck KGaA (now Mylan/Viatris) and served in the office of the President of Par Pharmaceuticals (US) for Merck Generics.
Read more
Ian has over 43 years of pharmaceutical industry experience. Prior to founding Juno/Cpoint in 2010, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010. He was instrumental in the development of Arrow’s international business units in South Africa and Brasil. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual Canadian sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Teva) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was Executive Vice President and General Manager of Genpharm, Canada. He was a Senior Executive in the international generics business of Amerpharm/Merck KGaA (now Mylan/Viatris) and served in the office of the President of Par Pharmaceuticals (US) for Merck Generics.
Read more
Ian has over 43 years of pharmaceutical industry experience. Prior to founding Juno/Cpoint in 2010, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010. He was instrumental in the development of Arrow’s international business units in South Africa and Brasil. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual Canadian sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Teva) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was Executive Vice President and General Manager of Genpharm, Canada. He was a Senior Executive in the international generics business of Amerpharm/Merck KGaA (now Mylan/Viatris) and served in the office of the President of Par Pharmaceuticals (US) for Merck Generics.
Read more
WHY PARTNER WITH JUNO
We are Juno, a global specialist company in the pharmaceuticals market. We are a team of innovative entrepreneurs, with years of collective healthcare industry experience and widespread international networks. Spanning across four continents, we offer an extensive product portfolio with a focus on niche and differentiated products.
We’re passionate about building bridges to unmet medical needs and supporting our customers and patient groups with access to pharmaceuticals. We constantly strive to find differentiated ways of engaging customers and identifying new opportunities. We are creative and committed partners with a focus on delivering value across the full spectrum of our industry.
Send us an email
Have a question about our products, partnering with us, career opportunities or would like to share any feedback or ideas with us?
Please use the form field below
Head Office
Juno Pharmaceuticals Inc.
555 Richmond Street West,
Suite 1004, Toronto,
Ontario M5V 3B1, Canada
+1 905 881 4410 Ext 203
Email: Jesse BucksteinBusiness Development
Juno Pharmaceuticals Inc.
1st Floor, The Coach House,
Cross Heyes,
Malmesbury SN16 9BE
+44 (0) 1666 848 450
Email: UK OfficeCANADA – Juno LP completes Exit of Searchlight Pharma Inc
Juno Pharmaceutical Limited Partners (“Juno LP”) has exited its equity investment in Searchlight Pharma Inc (“Searchlight”) to Apotex Inc (“Apotex”). Searchlight is a leading Canadian-based specialty healthcare company that executes best-in-class search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products. Searchlight’s core promoted products focus on women’s health, dermatology, allergy, pain […]
Companies
Know what Company you’re looking for or need help with your search?
Just use the search function below to find it by Country name or Category.
Our Location
The Juno team is always actively seeking new partnership opportunities. If you are interested in learning more about us, please contact our Corporate Development Director, Jesse: jessebuckstein@www.junopharm.com
